Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials

Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 6th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	ROE	ROA	ROCE	ROIC	D/E	Current Ratio	Gross Margin	Profit Margin	Operating Margin
BMY	BRISTOL MYERS SQUIBB CO	$127.71B	43.90%	10.50%	16.18%	18.00%	2.79	1.59	69.20%	18.50%	22.65%
BIIB	BIOGEN INC	$37.49B	1.90%	1.10%	1.58%	3.10%	0.69	1.95	74.00%	3.40%	4.32%
NVS	NOVARTIS AG	$304.86B	24.60%	8.60%	16.83%	24.50%	2.14	0.88	74.90%	17.50%	24.82%
ABBV	ABBVIE INC	$521.11B	-135.70%	4.70%	12.13%	16.40%	-23.58	0.81	71.50%	9.80%	17.61%
LLY	ELI LILLY & CO	$1.33T	83.60%	21.20%	34.40%	31.90%	2.68	1.39	83.60%	31.90%	40.21%
AMRN	AMARIN CORP PLC	$255.20M	-4.30%	-3.00%	-3.64%	-5.30%	0.43	3.50	40.90%	-10.90%	-9.48%
GILD	GILEAD SCIENCES INC	$211.70B	-21.70%	-7.20%	-3.86%	-4.00%	2.95	1.38	79.90%	-12.50%	-4.91%
AZN	ASTRAZENECA PLC	$289.31B	21.70%	9.10%	16.99%	29.20%	1.30	0.89	81.90%	17.00%	23.33%
AMGN	AMGEN INC	$251.94B	89.30%	9.50%	18.47%	18.00%	7.18	1.37	69.50%	23.00%	34.01%
MRK	MERCK & CO INC	$368.89B	6.60%	2.40%	7.54%	8.00%	2.09	1.32	73.00%	4.80%	11.56%
PFE	PFIZER INC	$173.95B	4.90%	2.10%	2.47%	3.70%	1.36	1.27	73.20%	6.80%	6.55%
SNY	SANOFI	$108.14B	5.70%	3.10%	6.00%	13.20%	0.86	0.99	72.80%	8.10%	11.91%
GRFS	GRIFOLS SA	$5.57B	7.20%	2.00%	6.45%	6.50%	2.30	2.51	38.00%	5.30%	15.18%
GSK	GSK PLC	$99.24B	24.50%	6.80%	11.12%	17.40%	2.84	0.86	72.60%	13.00%	16.90%
JNJ	JOHNSON & JOHNSON	$657.68B	19.60%	8.10%	13.19%	24.50%	1.42	1.02	67.60%	16.20%	18.85%
MDCX	MEDICUS PHARMA LTD	$2.38M	N/A	-415.30%	-271.46%	-3,558.20%	-16.35	1.57	N/A	N/A	N/A
OGN	ORGANON & CO	$3.63B	22.10%	1.60%	8.83%	7.40%	10.23	2.03	53.10%	3.50%	15.56%
SCLX	SCILEX HOLDING CO	$15.71M	N/A	-151.00%	168.05%	330.20%	-1.83	0.07	55.50%	-1,418.50%	-1,375.29%
NSRX	NASUS PHARMA LTD	$35.95M	-315.70%	-161.20%	-96.19%	-1,685.00%	0.13	8.77	N/A	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$23.03M	-121.20%	-118.10%	-132.07%	-239.00%	0.01	200.08	N/A	N/A	N/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 17 points higher than the general drug manufacturer industry average of 35.

BMY passed 19 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 36.96% over the past year, underperforming other general drug manufacturer stocks by -4 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $64.83, an upside of 3.77% from Bristol Myers Squibb Co's current stock price of $62.48.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 46.15% have issued a Strong Buy rating, 0% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: C, and AI: C.

Biogen (NASDAQ:BIIB) has a Due Diligence Score of 39, which is 4 points higher than the general drug manufacturer industry average of 35.

BIIB passed 12 out of 33 due diligence checks and has average fundamentals. Biogen has seen its stock return 69.52% over the past year, overperforming other general drug manufacturer stocks by 28 percentage points.

Biogen has an average 1 year price target of $260.86, an upside of 2.85% from Biogen's current stock price of $253.62.

Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 22 analysts covering Biogen, 40.91% have issued a Strong Buy rating, 31.82% have issued a Buy, 22.73% have issued a hold, while 4.55% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 30, which is -5 points lower than the general drug manufacturer industry average of 35. Although this number is below the industry average, our proven quant model rates NVS as a "B".

NVS passed 10 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 31.14% over the past year, underperforming other general drug manufacturer stocks by -10 percentage points.

Novartis Ag has an average 1 year price target of $136.00, a downside of -15.42% from Novartis Ag's current stock price of $160.79.

Novartis Ag stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Novartis Ag, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.64%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.47%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 226.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.03%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.47%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 55.6% indicates that its dividend yield is sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.98%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.47%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 94.5% indicates that its dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 2.21% in the last day, and up 7.09% over the last week. Astrazeneca was the among the top gainers in the drug manufacturers - general industry, gaining 7.02% yesterday.

AstraZeneca shares are trading higher after the company reported better-than-expected Q3 financial results.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 10 points higher than the general drug manufacturer industry average of 33. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 36.96% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -4 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 43, which is 10 points higher than the general drug manufacturer industry average of 33. It passed 3 out of 7 valuation due diligence checks.

Biogen's stock has gained 69.52% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 28 percentage points.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 71, which is 38 points higher than the general drug manufacturer industry average of 33. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -11.57% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -53 percentage points.

Are general drug manufacturer stocks a good buy now?

43.75% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to fall by -0.02% over the next year.

6.25% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 50% of general drug manufacturer stocks are rated B (Buy), 37.5% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 45.6x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Biogen (NASDAQ:BIIB)

3. Novartis Ag (NYSE:NVS)

1. Pfizer (NYSE:PFE)

2. Bristol Myers Squibb Co (NYSE:BMY)

3. Sanofi (NASDAQ:SNY)

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Biogen (NASDAQ:BIIB)

3. Grifols Sa (NASDAQ:GRFS)

Company

Stock Tools

Stock Ideas